| BUB1 |
BAY 1816032 |
BAY-283 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
300 nM |
human |
| PIP4K2A |
BAY-091 |
BAY-0361 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
1 - 10 µM |
human |
| PRKAA1, RPS6KA1 |
BAY-3827 |
BAY-974 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
150 nM |
human |
| MET |
BAY-474 |
BAY-827 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
0.001 - 1 µM |
human |
| ROCK1, ROCK2 |
BAY-549 |
BAY-4900 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
≤ 100 nM |
human |
| TIE1, TEK, DDR1, DDR2 |
BAY-826 |
BAY-309 |
Kinase domain (active site) |
Inhibitor (type 2, ATP competitive) |
≤ 0.5 µM |
human |
| MAPK7 |
BAY-885 |
BAY-693 |
Kinase domain (active site) |
Inhibitor (type 1.5, ATP competitive) |
1 µM |
human |
| TBK1, IKBKE |
BAY-985 |
BAY-440 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
≤ 1 µM |
human |
| AKT1, AKT2, AKT3 |
BAY1125976 |
BAY-940 |
Kinase domain (allosteric pocket) |
Covalent inhibitor (type 4, non-ATP competitive) |
≤ 1 µM |
human |
| IKBKB |
BI 605906 |
BI-5026 |
Kinase domain (active site) |
Inhibitor (ATP competitive) |
≤ 5 µM |
human |
| CIT |
C3TD879 |
C3TD879-N |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
≤ 2 µM |
human |
| SGK3 |
SGK3-PROTAC1 |
cisSGK3-PROTAC1 |
Kinase domain (active site) |
PROTAC degrader (ATP competitive) |
≤ 3 µM |
human |
| MAPK14 |
FS-694 |
FM-743 |
Kinase domain (active site) |
Inhibitor (type 1.5, ATP competitive) |
0.1 - 1 µM |
human |
| IRAK4 |
GNE-2256 |
GNE-6689 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
1 µM |
human |
| LIMK1 |
SM311 |
SM311-NC |
Active site (covalent binding to Cys349) |
Covalent inhibitor |
0.1 -1 µM |
human |
| LIMK2 |
THNAN69 |
THNAN69-NC |
ATP binding pocket |
Degrader |
10 - 100 nM |
human |
| CDK7 |
JNJ-3738 |
JNJ-6240 |
Kinase domain (active site) |
Covalent inhibtor (ATP competitive) |
≤ 1 µM |
human |
| CSNK1D, CSNK1E |
JNJ-6204 |
JNJ-0293 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
≤ 1 µM |
human |
| MAPK3, MAPK1 |
ERKi |
ERKi-NC |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
1 µM |
human |
| LRRK2 |
MLi-2 |
MLi-2-NC |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
≤ 1 µM |
human |
| SYK |
MRL-SYKi |
MRL-SYKi-NC |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
100 nM |
human |
| PTK2, PTK2B |
PF-04554878 |
PF-00911705 |
Kinase domain (active site) |
Inhibitor (ATP mimetic) |
100 nM |
human |
| DDR1, DDR2, MAPK11, MAPK14 |
SR-302 |
SR-301 |
Kinase domain (active site) |
Inhibitor (type 2, ATP competitive) |
100 nM |
human |
| MAPK14 |
SR-318 |
SR-321 |
Kinase domain (active site) |
Inhibitor (type 2, ATP competitive) |
< 100 nM |
human |
| MAPK14 |
Skepinone-L |
FM-743 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
1 µM |
human |
| panCLK (CLK1, CLK2, CLK3, CLK4) |
T3-CLK |
T3-CLK-N |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
< 100 nM |
human |
| ACVR1B, TGFBR1 |
TP-008 |
Al11 |
Kinase domain (active site) |
Inhibitor (type 1, ATP competitive) |
1 - 10 µM |
human |
| RIPK1 |
TP-030-1 |
TP-030n |
Kinase domain (allosteric pocket) |
Inhibitor (type 3, non-ATP competitive) |
100 nM |
human |
| RIPK1 |
TP-030-2 |
TP-030n |
Kinase domain (allosteric pocket) |
Inhibitor (type 3, non-ATP competitive) |
100 nM |
human |
| AKT1, AKT2, AKT3 |
Borussertib |
RL2578 |
Kinase domain (allosteric pocket) |
Covalent inhibtor (type 4, non-ATP competitive) |
1 µM |
human |